-transparent.png){kind=logo}
Pergolide mesylate, a semisynthetic ergoline and a potent, long-acting central dopamine agonist, was tested in 13 patients with advanced Parkinson disease and diurnal oscillations in performance ("wearing-off" or "on-off" phenomena or both) whose response to levodopa had diminished considerably. Among all nine patients who completed the initial clinical trial, pergolide alone (two patients) or combined with levodopa (seven patients) had a marked antiparkinson effect. There was a significant reduction (p less than 0.05) in rigidity, bradykinesia, gait disorder and total Parkinson disease disability score. Pergolide had a marked effect in all the patients with "wearing-off" or "on-off" phenomena or both, resulting in a significant increase (p less than 0.01) in the duration of the time patients were "on." the number of hours in which patients were "on" increased from 3.8 +/- 0.5 (SEM) to 11.4 +/0 ).8 (SEM). The main daily dose of pergolide was 2.4 mg (range, 2 to 5 mg). Ten months later, all nine patients are doing well. Pergolide is an effective drug in patients with advanced Parkinson disease and reduces "on-off" phenomena.
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
July 2002,
Revue neurologique,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
September 1982,
Annals of neurology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
October 1982,
Neurology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
April 1982,
Annals of internal medicine,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
August 2005,
Archives of neurology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
January 2002,
Clinical neuropharmacology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
January 2009,
Nederlands tijdschrift voor geneeskunde,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
July 2004,
Neurology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
March 2007,
Archives of neurology,
A Lieberman, and
M Goldstein, and
M Leibowitz, and
A Neophytides, and
M Kupersmith, and
V Pact, and
D Kleinberg
January 2004,
Clinical neuropharmacology,
